-
-
-
-
-
-
-
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
-
-
-
-
-
-
-
Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
-
-
-
-
-
-
-
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
-
-
-
-
-
-
-
Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) PDUFA Delay Signals FDA Receptivity - RBC
-
-
-
-
-
-
-
Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
-
-
-
-
-
-
-
Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
-
12,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All